PI
RLAY icon

Pennant Investors’s Relay Therapeutics RLAY Stock Holding History

Pennant Investors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-42,400
Closed -$276K – 41
2024
Q2 		$276K Hold
42,400
– – 0.07% 33
2024
Q1 		$352K Hold
42,400
– – 0.09% 32
2023
Q4 		$467K Buy
+42,400
New +$358K 0.1% 23

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Pennant Investors's RLAY Position: Q3 2024 in Review

Pennant Investors sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 42,400 shares — an estimated $276K sold.

Pennant Investors first reported a position in RLAY in Q4 2023 and held it in 3 quarters. The position peaked at $467K in Q4 2023. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Pennant Investors reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 42,400 Relay Therapeutics shares in Q3 2024, an estimated $276K.
  • Pennant Investors first reported a position in Relay Therapeutics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Relay Therapeutics position peaked at $467K in Q4 2023.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.